AAA_AGN - pending

Source: Streetwise Reports (4/26/22)

Algernon AGN announces Repirinast results and last patient treated in Phase 2 trial of Ifenprodil. Sent several emails/left messages for Chris Moreau, but reaching out to PennyQueen others to go from there.

Cannabis Firm Increases YOY Revenue By 352% in 2021
(04/12/2022)

The company is expected to outperform again in 2022 given its focus on strategic growth and acquisitions, noted a Noble Capital Markets report.

Cannabis Infused Beverage Company Stock in 'Very Good Spot' to Purchase
Source: Clive Maund (04/04/2022)

Technical analyst Clive Maund explains why he rates this company a strong speculative buy.

Mental Health Co. Hosts Phase II Trials for LSD, Psilocybin
Source: Streetwise Reports (03/16/2022)

This mental health company is pioneering a unique, new treatment for mental health issues such as depression and PTSD in which psychedelics are administered by medical professionals in specialized clinics.

Despite a dampened Q1 FY22 performance and an uncertain future, parts of a cannabis firm's story remain attractive, warranting a Market Perform rating, noted a Noble Capital Markets report.

Cannabis Cos. Expected to Post Better Revenues As of Q2/22
Source: Streetwise Reports (02/18/2022)

Whereas U.S. multistate cannabis operators are expected to do well in 2022, federal legalization of cannabis would give a jolt to companies of all sizes, noted a ROTH Capital Partners report.